<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: It has been shown that the presence on diagnosis of endoscopic macroscopic markers indicates a high-risk group for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>AIM: To determine whether <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy prior to diagnosis of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> influences markers for risk development of subsequent high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A review of <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> entering a surveillance programme was undertaken </plain></SENT>
<SENT sid="3" pm="."><plain>Five hundred and two patients diagnosed with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> were assessed on diagnosis for endoscopic macroscopic markers or low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Subsequent development of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> was documented </plain></SENT>
<SENT sid="5" pm="."><plain>The relationship between the initiation of <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy prior to the diagnosis of BE and the presence of macroscopic markers or low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> at entry was determined </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Fourteen patients developed high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> during surveillance </plain></SENT>
<SENT sid="7" pm="."><plain>Patients who entered without prior <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy were 3.4 times (95% CI: 1.98-5.85) more likely to have a macroscopic marker or low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> than those patients already on a <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Use of <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy prior to diagnosis of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> significantly reduced the presence of markers used to stratify patient risk </plain></SENT>
<SENT sid="9" pm="."><plain>Widespread use of <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> will confound surveillance strategies for patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> based on entry characteristics but is justified because of the lower risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> </plain></SENT>
</text></document>